Your browser doesn't support javascript.
loading
Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas.
Gil, Joan; Marques-Pamies, Montserrat; Jordà, Mireia; Fajardo-Montañana, Carmen; García-Martínez, Araceli; Sampedro, Miguel; Serra, Guillermo; Salinas, Isabel; Blanco, Alberto; Valassi, Elena; Sesmilo, Gemma; Carrato, Cristina; Cámara, Rosa; Lamas, Cristina; Casano-Sancho, Paula; Alvarez, Clara V; Bernabéu, Ignacio; Webb, Susan M; Picó, Antonio; Marazuela, Mónica; Puig-Domingo, Manel.
Afiliação
  • Gil J; Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Marques-Pamies M; Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Jordà M; Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Fajardo-Montañana C; Department of Endocrinology, Hospital Universitario de La Ribera, Alzira, Spain.
  • García-Martínez A; Hospital General Universitario de Alicante-Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Sampedro M; Biomedical Research Networking Center in Rare Diseases (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Serra G; Biomedical Research Networking Center in Rare Diseases (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Salinas I; Department of Endocrinology and Nutrition, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, Madrid, Spain.
  • Blanco A; Department of Endocrinology and Nutrition, Son Espases University Hospital, Palma de Mallorca, Spain.
  • Valassi E; Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Sesmilo G; Department of Neurosurgery, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Carrato C; Department of Endocrinology/Medicine, CIBERER U747, ISCIII, Research Center for Pituitary Diseases, Hospital Sant Pau, IIB-SPau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Cámara R; Department of Endocrinology and Nutrition, Hospital Universitari Dexeus, Barcelona, Spain.
  • Lamas C; Department of Pathology, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Casano-Sancho P; Department of Endocrinology and Nutrition, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Alvarez CV; Department of Endocrinology and Nutrition, Hospital General Universitario de Albacete, Albacete, Spain.
  • Bernabéu I; Biomedical Research Networking Center in Rare Diseases (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Webb SM; Institut de Recerca Pediàtrica, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Spain.
  • Picó A; Neoplasia & Endocrine Differentiation P0L5, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), University of Santiago de Compostela (USC), Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain.
  • Marazuela M; Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS)-SERGAS, Santiago de Compostela, Spain.
  • Puig-Domingo M; Department of Endocrinology/Medicine, CIBERER U747, ISCIII, Research Center for Pituitary Diseases, Hospital Sant Pau, IIB-SPau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Clin Endocrinol (Oxf) ; 94(5): 811-819, 2021 05.
Article em En | MEDLINE | ID: mdl-32978826
OBJECTIVE: Large somatotrophic adenomas depict poor response to somatostatin receptor ligands (SRLs). Debulking has shown to enhance SRLs effect in some but not all cases and tumour volume reduction has been proposed as the main predictor of response. No biological studies have been performed so far in this matter. We aimed to identify molecular markers of response to SRLs after surgical debulking in GH-secreting adenomas. DESIGN: We performed a multicenter retrospective study. PATIENTS: 24 patients bearing large GH-producing tumours. MEASUREMENTS: Clinical data and SRLs response both before and after surgical debulking were collected, and 21 molecular biomarkers of SRLs response were studied in tumour samples by gene expression. RESULTS: From the 21 molecular markers studied, only two of them predicted enhanced SRLs response after surgery. Tumours with improved response to SRLs after surgical debulking showed lower levels of Ki-67 (MKI67, FC = 0.17 and P = .008) and higher levels of RAR-related orphan receptor C (RORC) (FC = 3.1 and P Ë‚ .001). When a cut-off of no detectable expression was used for Ki-67, the model provided a sensitivity of 100% and a specificity of 52.6% with an area under the curve of 65.8%. Using a cut-off of 2 units of relative expression of RORC, the prediction model showed 100% of sensitivity and specificity. CONCLUSIONS: High levels of RORC and low levels of Ki-67 identify improved SRLs response after surgical debulking in large somatotropic adenomas. To determine their expression would facilitate medical treatment decision-making after surgery.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Acromegalia / Adenoma Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Acromegalia / Adenoma Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha